Including both patients receiving chemotherapy in the neoadjuvant setting (i.e. evaluated by pathologic response in the primary tumor) and patients with advanced disease (i.e., evaluated by RECIST 1.1) represent another inherent limitation of the present study.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}